Origanum majorana L. extract alleviates dexamethasone-induced hepatotoxicity, oxidative stress and pathological alterations in vivo

Bulletin of the National Research Centre

Table 2 O. majorana aqueous extract preventive role on the level of liver MDA, GSH, the activities of GST, CAT, GPx, and GR against DXM treatment

Parameters Treatments	MDA (nmol/g Tissue/hr)	% change	GSH (nmol/g tissue)	% change	GST IU/gm tissue	% change	CAT (IU/gm tissue)	% change	GPx (IU/gm tissue)	% change	GR (IU/gm tissue)	% change
G1 Control	13.1 ± 1.1	–	33.5 ± 3.7	–	4.1 ± 0.2	–	0.80 ± 0.004	–	171.5 ± 8.4	–	317.2 ± 12.6	–
G2 DXM	25.7 ± 1.7^***	95.9	18.5 ± 1.4 ^**	− 44.8	2.3 ± 0.2 ^***	− 43.2	0.213 ± 0.01 ^***	− 73.4	81.6 ± 6.1^***	− 52.4	180.1 ± 5.7^***	− 43.2
G3 DXM + O. majorana	22.0 ± 0.1	− 14.4	31.8 ± 2.4 ^***	72.2	3.6 ± 0.1 ^***	55.6	0.363 ± 0.1 ^**	− 70.4	176.6 ± 4.0 ^**	116.5	267.8 ± 13.4^***	48.7
F-Probability	P < 0.0001	–	P < 0.0020	–	P < 0.0001	–	P < 0.0001	–	P < 0.0001	–	P < 0.0001	–

Data are mean ± SE, (n = 6), G1 compared to G2 and G3 compared to G2
DXM Dexamethasone
*, ** and *** Indicate significant change from control, DXM, and DXM + O. majorana, respectively, at P < 0.0001